<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031859</url>
  </required_header>
  <id_info>
    <org_study_id>PSMMC &amp; KAAUH</org_study_id>
    <nct_id>NCT04031859</nct_id>
  </id_info>
  <brief_title>Risk Stratification Procedure for Thromboembolism Prophylaxis</brief_title>
  <official_title>The Effectiveness of a Risk Stratification Procedure for Thromboembolism Prophylaxis After Total Knee Replacement Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Saudi Arabia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prince Sultan Military College of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiti Sains Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Saudi Arabia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective for this study is validation for the proposed risk stratification tool, by
      evaluating the clinical outcomes for its use post TKR Surgeries. For this objective, the
      design that is used is Randomized Trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients that will have total knee replacement, in a given period of time in both medical
      centers; Prince Sultan Military Medical City (PSMMC) and King Abd Allah University Hospital
      (KAAUH) in Princess Noura University, will be randomly separated into 2 groups; in the first
      group (A): Venous thromboembolism (VTE) risk stratification tool (which is prepared by a
      clinical pharmacist) will be applied to choose the tailored extended VTE prophylactic agent.
      While in the second group (B), the risk stratification tool will not be used, rather it will
      follow the routine hospital protocol for choosing the VTE prophylactic agent, which is
      Caprini: a standard validated model. Then each group of patients will be followed till 35
      days post‚Äêoperation, during which all VTE or bleeding events should be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 14, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism (VTE) complications</measure>
    <time_frame>35 days post total Knee Replacement surgery</time_frame>
    <description>Deep vein thrombosis, pulmonary embolism, sudden death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>35 days post total Knee Replacement surgery</time_frame>
    <description>Major or minor bleeding will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>35 days post total Knee Replacement surgery</time_frame>
    <description>Surgical site infection post operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Total Knee Replacement Surgeries</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group a VTE risk stratification procedure will be used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>VTE risk stratification procedure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female patients who are planned for elective TKR surgery (primary only).

          2. Agreed to sign the Informed consent form (ICF).

          3. Patients aged older than 18 years.

        Exclusion Criteria:

          1. Patients receiving anticoagulant for treatment.

          2. Patients with a history of DVT or PE were excluded from the study due to the marked
             increase in the risk of recurrent VTE compared to the general risk of (7% vs. 0.1%);
             (Fahrni, 2015).

          3. Patients with renal or hepatic failure, renal failure is defined as end-stage kidney
             disease (on dialysis); hepatic failure is defined as complete liver cirrhosis.

          4. Pregnant woman.

          5. Revision surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariam Alameri, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Sains Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince Sultan Medical Military City</name>
      <address>
        <city>Riyadh</city>
        <zip>00966</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Saudi Arabia</investigator_affiliation>
    <investigator_full_name>Mariam Ahmad Alameri, Clinical Pharmacist</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Total Knee Replacement</keyword>
  <keyword>Venous thromboembolism (VTE)</keyword>
  <keyword>Risk Stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

